Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | MBS8 |
| Synonyms | |
| Therapy Description |
MBS8 is a micellar formulation of a TLR7 agonist, which may enhance anti-tumor immune response (Cancer Res (2023) 83 (7_Supplement): 1820). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| MBS8 | MBS 8|MBS-8|MBS8(|V270) | TLR7 Agonist 14 | MBS8 is a micellar formulation of a TLR7 agonist, which may enhance anti-tumor immune response (Cancer Res (2023) 83 (7_Supplement): 1820). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04855435 | Phase I | MBS8 MBS8 + Pembrolizumab | Safety and Preliminary Efficacy of MBS8(1V270) in Cancer Patients With Advanced Solid Tumours | Recruiting | ESP | DNK | 0 |